# OnCo record nct05999994 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05999994/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05999994", "NCT05999994" ;
  schema:name "A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer"@en ;
  schema:alternateName "CAMPFIRE"@en ;
  schema:description "A phase 2 trial of Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel and Abemaciclib in advanced solid tumours, run by Eli Lilly and Company, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05999994/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05999994> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2020-01-22" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vinorelbine/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/abemaciclib/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> .